Apr 5, 2018 | age-related macular degeneration (ARMD), Clinical Trials, Information, Latest News, Stem cells
Treating Vision Loss A UCSB team helped create a retinal implant designed to replace support cells damaged by dry age-related macular degeneration By Julie Cohen The trial is ongoing and the team continues to analyze more patients. While the preliminary results are...
Nov 14, 2017 | age-related macular degeneration (ARMD), Clinical Trials, Information, Latest News, macular degeneration, Our Blog
In the “wet” type of macular degeneration, abnormal blood vessels (known as choroidalneovascularization or CNV) grow under the retina and macula. These new blood vessels may then bleed and leak fluid, causing the macula to bulge or lift up from its normally flat...
Oct 5, 2017 | AMD Research, Clinical Trials, Dry Macular Degeneration, Information, Latest News, Macular Degeneration Treatment, Our Blog
New research in Phase II clinical trials New drug reduces rate of progression of incurable eye disease by Nicola Webber An international study including researchers from the Centre for Eye Research Australia (CERA) has found a way to slow the progression of dry...
May 24, 2017 | age-related macular degeneration (ARMD), AMD Research, Clinical Trials, Information, Latest News, macular degeneration, Stem cells
This is still in the very early stages of research.They have started phase II of the clinical trials. Retinal Pigment Epithelial Transplant Geographic Atrophy By: Michael Johnson, MD – Eastern Maine Medical Center For years, people were throwing away cells that could...
May 19, 2017 | age-related macular degeneration (ARMD), Clinical Trials, Information, Latest News, Our Blog, Wet macular degeneration
This is research is taking place in London, England. It has a long road ahead. Once it comes over to America it will need to go through clinical trails and be approved by the FDA. This would be a big help to be used in conjunction to the eye injections. Say goodbye to...
May 9, 2017 | age-related macular degeneration (ARMD), AMD Research, Clinical Trials, Dry Macular Degeneration, macular degeneration, Our Blog
BioTime Announces New Positive Data from OpRegen® Trial in Dry-AMD ALAMEDA, Calif.–(Business Wire)–BioTime, Inc., a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced new data from...
Recent Comments